ARECOR THERAPEUTICS -01
Research ARECOR THERAPEUTICS -01 (6UI) on Bullrun: market cap EUR 20.95M, P/E 27.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6UI
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 20.95M
- P/E27.8
- Financial periodFY2025
- RevenueGBP 1.71M
- Revenue growth-66.1%
- Net incomeGBP 664.00K
- Free cash flow-GBP 2.46M
- Gross margin73.9%
Valuation Snapshot
latest market cap is EUR 20.95M; P/E is 27.8.
Peer valuation comparison
Latest P/E is 27.75x versus a Healthcare sector median of 24.46x (13.5% above).
Latest P/E is 27.75x versus a United Kingdom median of 16.18x (71.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 1.71M | GBP 664.00K | -GBP 2.46M | 73.9% | 0.02 | GBP 3.00M | GBP 98.00K | GBP 6.45M |
| FY2024 | GBP 5.05M | -GBP 10.24M | -GBP 9.18M | 30.5% | -0.31 | GBP 3.24M | GBP 232.00K | GBP 5.35M |
| FY2023 | GBP 4.57M | -GBP 8.55M | -GBP 5.99M | 27.4% | 0 | GBP 5.09M | GBP 338.00K | GBP 9.53M |
| FY2022 | GBP 2.40M | -GBP 9.26M | -GBP 11.13M | n/a | -0.32 | GBP 4.77M | GBP 288.00K | GBP 17.46M |
| FY2021 | GBP 1.16M | -GBP 6.17M | -GBP 5.52M | 100.0% | n/a | GBP 18.32M | GBP 231.00K | GBP 18.55M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 20.95M | 27.8 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ARECOR THERAPEUTICS -01
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ARECOR THERAPEUTICS -01's market cap?
ARECOR THERAPEUTICS -01's market capitalization is EUR 20.95M.
What is ARECOR THERAPEUTICS -01's P/E ratio?
ARECOR THERAPEUTICS -01's price-to-earnings (P/E) ratio is 27.8.
What does ARECOR THERAPEUTICS -01 do?
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.